trending Market Intelligence /marketintelligence/en/news-insights/trending/G0WoaiY4npppFX0KFep32w2 content esgSubNav
In This List

Catabasis Pharmaceuticals to execute 1-for-10 reverse stock split

Blog

Insight Weekly: Unease roils markets; US likely to slip into recession; firms' cash ratios fall

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch


Catabasis Pharmaceuticals to execute 1-for-10 reverse stock split

Catabasis Pharmaceuticals Inc. said its shares will start trading on the Nasdaq Global Market on a 1-for-10 reverse split-adjusted basis on Dec. 31 under the symbol CATB.

The majority shareholders of the company approved the reverse stock split on Dec. 12 and authorized the board to select a ratio for the split ranging from 1-for-5 to 1-for-15.

The Catabasis board approved the reverse stock split on Dec. 19 to help the company maintain its listing on the Nasdaq Global Market by complying with the exchange's minimum bid price requirement.

The action reduces the number of the company's outstanding common shares to about 7.1 million from about 71 million.

Cambridge, Mass.-based Catabasis is developing a treatment for Duchenne muscular dystrophy.